ISA-104 is under clinical development by ISA Pharmaceuticals and currently in Phase II for Hepatitis B. According to GlobalData, Phase II drugs for Hepatitis B have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISA-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISA Pharmaceuticals overview
ISA Pharmaceuticals is a developer of synthetic therapeutic vaccines for the treatment of cancer and persistent viral infections. The company’s pipeline products include ISA101, an immunotherapeutic vaccine for cervical cancer, MyISA, a personalized immunotherapy based on neoantigens to eradicate cancer; ISA203, preferentially expressed antigen in melanoma for treating different types of cancers; and ISA204 for the treatment of hepatitis B. It also develops synthetic long peptides technology used in the applications of viral and non-viral targets and provides multiple products for persistent virus infections. The company also provides amplivant technology, which is based on a proprietary and synthetic toll-like receptor agonist and is used in new generation immunotherapeutic for treating various diseases. ISA Pharmaceuticals is headquartered in Leiden, the Netherlands.
For a complete picture of ISA-104’s drug-specific PTSR and LoA scores, buy the report here.